Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CCR9 | P51686 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482358 | 0.97 | FFAR4 (0.41) | FFAR4MDM2MAPTKDM4ETHRB | |
| SCHEMBL1482371 | 0.91 | FFAR4 (0.47) | FFAR4NR1H4MDM2MAPTTHRB | |
| SCHEMBL1484289 | 0.88 | FFAR4 (0.49) | FFAR4NR1H4MDM2MAPTKDM4E | |
| SCHEMBL1483423 | 0.85 | NR1H4 (0.42) | NR1H4KDM4EP2RX3CCR9 | |
| SCHEMBL1482613 | 0.85 | KDM4E (0.45) | FFAR4MDM2KDM4EENPP2KMT2A | |
| SCHEMBL1482823 | 0.84 | THRB (0.45) | MAPTTHRBP2RX3ENPP2TP53 | |
| SCHEMBL1482428 | 0.84 | MAPT (0.52) | MAPTKDM4ETHRBP2RX3KMT2A | |
| SCHEMBL1482734 | 0.84 | MAPT (0.42) | MAPTKDM4ETHRBP2RX3KMT2A | |
| SCHEMBL1482727 | 0.83 | MAPT (0.40) | FFAR4MAPTKDM4ETHRBP2RX3 | |
| SCHEMBL1483050 | 0.82 | KDM4E (0.43) | NR1H4KDM4EP2RX3CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | FFAR4 1845/4885NR1H4 776/4885MDM2 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.